NIH Director Jay Bhattacharya testified before the Senate Appropriations Committee on Thursday morning to discuss the fiscal 2027 budget request [1].
The testimony centers on a significant shift in federal research priorities. The proposed funding cuts represent a move by the Trump administration to redefine the scope of government-funded science and reduce federal expenditures.
Bhattacharya appeared before the committee at the U.S. Capitol in Washington, D.C., on May 21, 2026 [2]. The session focused on the administration's request for the 2027 fiscal year, which includes a proposed $5 billion reduction in NIH funding [3].
According to the White House, these cuts are necessary to curb wasteful spending and eliminate what the administration describes as risky research [3]. The hearing provided a venue for senators to question how these reductions will impact ongoing medical studies, and the overall landscape of public health research in the U.S.
This budget proposal marks a departure from previous funding trajectories for the agency. The administration's focus on eliminating waste suggests a more stringent review process for grants and research initiatives moving forward [3].
Bhattacharya's testimony serves as the primary introduction of these fiscal goals to the legislative body responsible for appropriations. The committee must now weigh the administration's goals of fiscal restraint against the potential loss of scientific advancement resulting from the $5 billion cut [1].
“A proposed $5 billion reduction in NIH funding”
The proposed $5 billion cut signals a pivot toward a more restrictive federal research agenda. By targeting 'risky research' and 'wasteful spending,' the administration is likely attempting to redirect the NIH away from certain types of exploratory or controversial science toward more conservative or immediate clinical applications.
